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Atherosclerotic cardiovascular disease (CVD) represents the largest cause of mortality in end-
stage renal disease (ESRD). CVD in ESRD is not explained by classical CVD risk factors such as HDL 
cholesterol mass levels making functional alterations of lipoproteins conceivable. HDL functions in 
atheroprotection by promoting reverse cholesterol transport (RCT), comprising cholesterol efflux from 
macrophage foam cells, uptake into hepatocytes and final excretion into the feces. ESRD-HDL (n = 15) 
were compared to healthy control HDL (n = 15) for their capacity to promote in vitro (i) cholesterol efflux 
from THP-1 macrophage foam cells and (ii) SR-BI-mediated selective uptake into ldla[SR-BI] cells as well 
as (iii) in vivo RCT. Compared with HDL from controls, ESRD-HDL displayed a significant reduction in 
mediating cholesterol efflux (p < 0.001) and SR-BI-mediated selective uptake (p < 0.01), two key steps 
in RCT. Consistently, also the in vivo capacity of ESRD-HDL to promote RCT when infused into wild-
type mice was significantly impaired (p < 0.01). In vitro oxidation of HDL from healthy controls with 
hypochloric acid was able to fully mimic the impaired biological activities of ESRD-HDL. In conclusion, 
we demonstrate that HDL from ESRD patients is dysfunctional in key steps as well as overall RCT, likely 
due to oxidative modification.
Plasma levels of high density lipoprotein (HDL) cholesterol are strongly inversely correlated with the risk of ath-
erosclerotic cardiovascular disease (CVD) in populations with normal kidney function1,2. The beneficial effects 
of HDL are largely ascribed to the role of HDL in reverse cholesterol transport (RCT), i.e. the transport of excess 
cholesterol from the periphery back to the liver for excretion into bile2–4. For efficient RCT two steps are of critical 
importance, (i) cholesterol efflux from macrophage foam cells mainly mediated by ABCA1 and ABCG12,5 and (ii) 
SR-BI-dependent cholesterol uptake into hepatocytes2,6.
CVD represents the single largest cause of morbidity and mortality in patients with reduced kidney func-
tion or uremia, reflected by a 30-fold increase in age-adjusted CVD mortality in end-stage renal disease (ESRD) 
patients7,8. Although a number of classical as well as non-classical risk factors have been reported to contribute 
to this excessive increase in CVD mortality, the underlying pathophysiological basis for these observations is 
still insufficiently understood9. Chronic kidney disease itself might not result in a substantial impairment of the 
cholesterol efflux function of HDL10, while HDL from patients on hemodialysis exhibits an apparent reduction in 
the capacity to accept cholesterol from macrophages11–14. However, the ability of ESRD-HDL to function in the 
whole RCT pathway has not been investigated thus far.
Therefore, the present study not only tested the functional properties of HDL from ESRD patients for the two 
major steps of RCT in vitro, namely cholesterol efflux from macrophages and SR-BI-mediated cholesterol delivery 
but also the ability of ESRD-HDL to promote RCT from 3H-cholesterol-loaded macrophages in vivo in mice. Our 
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results indicate that ESRD-HDL is less efficient than control HDL in mediating RCT, conceivably due to oxidative 
modifications of HDL apolipoproteins.
Results
HDL from ESRD patients displays defective cholesterol uptake as well as cholesterol delivery 
properties in vitro. Two important functional properties enable HDL to serve as an efficient mediator of 
RCT, namely (i) to elicit cholesterol efflux from macrophage foam cells and (ii) to deliver cholesterol to cells 
via the SR-BI-mediated selective uptake pathway. To test these properties for HDL from ESRD patients we first 
performed cholesterol efflux experiments. Compared with HDL from control subjects, ESRD-HDL displayed a 
significant reduction in mediating cholesterol efflux (5.87 ± 0.26 vs. 4.05 ± 0.41%, p < 0.001, Fig. 1a). Next, we 
tested the capacity of ESRD-HDL to deliver cholesterol into ldla cells stably transfected with SR-BI. Also cellular 
cholesterol uptake from ESRD-HDL via SR-BI was significantly impaired for HDL from ESRD patients compared 
with controls (20.2 ± 1.2 vs. 13.4 ± 1.6%, p < 0.001, Fig. 1b). These data demonstrate that ESRD-HDL is defective 
in both properties crucial for functional RCT.
HDL from ESRD patients displays an altered lipid and protein composition. Compared with 
controls, HDL particles from ESRD patients were significantly enriched in triglycerides (Supplemental Table S2, 
p = 0.001). While the cholesteryl ester content of HDL was decreased in ESRD patients (p < 0.05), free choles-
terol content was increased (p < 0.05). Phospholipid and protein contents did not differ between the two exper-
imental groups. Regarding HDL proteins associated with impaired functionality of the particle we found ESRD 
HDL significantly enriched in both serum amyloid A (SAA, 27.4 ± 5.5 vs. 3.1 ± 0.5 μ g/dl, p < 0.001) and apoC-III 
(10.3 ± 0.7 vs. 8.1 ± 0.8 mg/dl, p < 0.05).
In ESRD patients, HDL cholesterol was positively associated with both the efflux (r = 0.58, p < 0.05) and selec-
tive uptake function (r = 0.53, p < 0.05), while no correlations were detected with the HDL triglyceride content. 
In addition, SAA within HDL correlated inversely to efflux (r = − 0.71, p < 0.01) but not significantly to selective 
uptake (r = − 0.43, p = 0.11). No correlations were found with the apoC-III content of HDL and either efflux 
(r = − 0.26, n.s.) or selective uptake (r = − 0.12, n.s.).
HDL from ESRD patients is defective in mediating RCT in vivo. Since HDL from ESRD patients 
showed impaired cholesterol uptake and delivery properties in vitro, we next tested the functional behaviour of 
ESRD-HDL in an integrated in vivo physiological setting of RCT. Mice that had received macrophage foam cells 
loaded with radioactively labeled cholesterol were infused with either PBS, control HDL or ESRD-HDL, and 
appearance of the tracer in different compartments was followed over time.
First, we assessed mass changes in cholesterol in the plasma compartment in response to the different treat-
ments. As shown in Fig. 2a, only the group receiving control HDL exhibited an increase in plasma total choles-
terol at the early 4 h time point, essentially due to significantly higher plasma free cholesterol levels (p < 0.01, 
Fig. 2b). The group receiving the ESRD-HDL was not different in these parameters from PBS controls. In agree-
ment with the mass data also appearance of macrophage-derived 3H-cholesterol in plasma was only higher at the 
4 h time point in the control-HDL group (p < 0.05, Fig. 2c). These data are consistent with ESRD-HDL having a 
reduced capacity to elicit cholesterol efflux in vivo analogous to our in vitro findings.
At the 48 h time point livers from PBS injected mice contained significantly less macrophage-derived 
3H-cholesterol (2.97 ± 0.10%) than livers from mice infused with either control HDL (4.10 ± 0.23%, p < 0.05) or 
ESRD-HDL (3.78 ± 0.14%, p < 0.05), while there was no difference between control and ESRD-HDL receiving 
groups.
Cholesterol can either be excreted from the body within the fecal neutral sterol fraction or after metabolic 
conversion to bile acids. The mass fecal excretion of neutral sterols (Fig. 2d) and bile acids (Fig. 2e) did not 
change upon the different treatments. On the other hand, control HDL resulted in a significant increase in tracer 
excretion within neutral sterols (Fig. 2f) as well as within bile acids (p < 0.05 for ESRD, p < 0.01 for PBS, Fig. 2g) 
Figure 1. ESRD-HDL displays defective cholesterol uptake as well as cholesterol delivery properties.  
(a) Cholesterol efflux from primary mouse peritoneal macrophages towards HDL from ESRD-patients (n = 15) 
compared with healthy control subjects (n = 15). (b) Cellular SR-BI mediated selective cholesterol uptake from 
ESRD-HDL or control HDL (each n = 15) into ldla cells stably transfected with SR-BI. Data are presented as 
means ± SEM. ***p < 0.001.
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causing an overall substantial increase in RCT. However, ESRD-HDL failed to have any significant effect on the 
fecal exretion of the macrophage-derived 3H-cholesterol, indicating that the in vivo capacity to mediate effective 
RCT is significantly impaired in these particles in comparison to HDL from healthy controls.
Oxidation of control HDL in vitro results in impaired cholesterol uptake as well as delivery properties. 
Since ESRD patients show a substantial increase in inflammatory load and oxidative stress15–17, we speculated 
that a possible mechanism underlying the decreased RCT functionality of ESRD-HDL might be oxidation of 
apolipoproteins contained within the HDL particle, which are of crucial importance to its function. Therefore, 
we next determined TBARS levels within HDL as a measure of oxidative modification. While in control HDL 
TBARS were detectable at a considerably low level, all ESRD-HDL tested contained substantial amounts of 
TBARS consistent with our hypothesis (0.7 ± 0.1 vs. 4.2 ± 0.6 nmol/mg, p < 0.001). In addition, TBARS content 
of HDL correlated negatively with the two functional parameters determined in our study, namely cholesterol 
efflux (r = − 0.58, p = 0.02) and selective uptake (r = − 0.52, p < 0.05). Further, we aimed to test the pathophysio-
logical consequences of HDL oxidation on the two functional properties important for RCT, cholesterol uptake 
and delivery. HDL oxidatively modified by incubation with HOCl displayed a significantly reduced capacity 
to serve as acceptors for macrophage-mediated cholesterol efflux compared with control HDL (7.02 ± 0.36 vs. 
4.96 ± 0.28%, p < 0.01, Fig. 3a). In addition, also the SR-BI-mediated uptake of cholesterol from oxidized HDL 
was significantly decreased (21.3 ± 0.7 vs. 15.5 ± 0.8%, p < 0.01, Fig. 3b). These data show that in vitro oxidatively 
modified HDL are defective in both properties, mediating cholesterol efflux and delivering cholesterol to cells via 
SR-BI, comparable with the functional deficits observed for ESRD-HDL.
Figure 2. HDL from ESRD patients are defective in medicating RCT in vivo. Mice injected with macrophage 
foam cells loaded with radioactively labelled 3H-cholesterol were infused with either PBS, control HDL or 
ESRD-HDL as detailed in methods. (a) Mass changes in plasma total cholesterol, (b) mass changes in plasma 
free cholesterol, (c) appearance of the 3H-cholesterol tracer in plasma, (d) mass fecal neutral sterol excretion 
over 48 h, (e) mass fecal bile acid excretion over 48 h, (f) fecal 3H-cholesterol tracer excretion within neutral 
sterols, (g) fecal 3H-cholesterol tracer excretion within bile acids. Data are presented as means ± SEM, n = 6–8 
mice/group. *p < 0.05, **p < 0.01.
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HDL oxidized in vitro is defective in mediating in vivo RCT. Next, we tested the in vivo func-
tionality of oxidized HDL in RCT. HOCl-modified HDL had a significantly decreased capacity to mobilize 
macrophage-derived 3H-cholesterol to the plasma compartment compared with native HDL at the 48 h time 
point (p < 0.05, Fig. 4a). In addition, counts recovered in the fecal neutral sterol fraction (p < 0.01, Fig. 4b) as well 
as in the fecal bile acid fraction (p < 0.05, Fig. 4c) were significantly lower with HOCl-modified HDL, indicating 
that oxidative modification of healthy control HDL substantially decreases its in vivo capacity to function in RCT.
Discussion
Combined, the results of this study demonstrate that HDL from patients with ESRD is dysfunctional in mediating 
RCT, a key atheroprotective property2,3, conceivably due to extensive oxidative modifications of HDL associated 
proteins. Reduced RCT is thus expected to contribute to the excessive increase in CVD risk observed in ESRD 
patients.
A progressive reduction in kidney function is known to associate with a significant increase in CVD risk7,8,18. 
This relationship culminates in an approximately 30-fold increase in age-adjusted CVD risk in ESRD patients7,8. 
Plasma HDL cholesterol levels in ESRD patients are decreased19,20, however, to our knowledge the ability of 
HDL particles from ESRD patients to function in overall RCT has not been investigated thus far. In the present 
study we used in addition to in vitro studies an in vivo approach to directly measure RCT from macrophages to 
feces3,5,6,21. Our data thereby add a reduction in the RCT functionality of HDL to pathophysiological concepts of 
increased CVD in patients with reduced kidney function and uremia.
An interesting question is the underlying pathophysiology and therefore the mechanistic basis for the oxidative 
modifications observed in this study within HDL apolipoproteins in ESRD. It is established that ESRD patients 
display a proinflammatory state and suffer from an increased oxidative stress burden22–24. Myeloperoxidase 
(MPO) is an enzyme expressed by macrophages and neutrophils that is released in response to proinflammatory 
stimuli25. Interestingly, plasma levels of MPO have been shown to be significantly increased in patients with ESRD 
and also to be a predictor of mortality in hemodialysis patients26,27. MPO has been previously demonstrated to 
cause oxidative modifications of HDL apolipoproteins that might impact their functionality25,28. Hypochloric acid 
(HOCl) can mimic MPO-induced oxidation in vitro. By modifiying HDL from healthy controls with HOCl we 
were able to replicate the functional deficits displayed by ESRD-HDL, namely a decreased efficacy in promoting 
cholesterol efflux as well as a reduced ability to deliver cholesterol to cells via SR-BI. These data provide an addi-
tional line of evidence that MPO might play a key role in causing the decreased functionality of HDL in ESRD 
and that MPO might therefore represent an interesting target for pharmacological inhibition in ESRD patients.
Testing HDL functionality in addition to measuring mass HDL cholesterol and apoA-I levels is an emerging 
concept in the field of HDL research29–32. However, although multiple potentially beneficial effects have been 
described for HDL33, there are limitations for the clinical setting, since reliable and reproducible assays to test 
these functions are lacking30. Thus far, several dysfunctionalities were ascribed to HDL from ESRD patients. It 
was reported that ESRD is less effective in protecting LDL against copper mediated oxidation in vivo34. These 
data could be interpreted as a further indication that HDL from ESRD patients is already oxidized to a substan-
tial extent and therefore cannot properly fulfil anti-oxidative functions. Furthermore, a decreased functionality 
of HDL-mediated cholesterol efflux has been demonstrated in ESRD patients11,35. Regarding testing properties 
related to RCT in vitro our data suggest that also assays addressing selective uptake through SR-BI from given 
HDL preparations might be valuable, since this also represents a key step for effective RCT that might be differ-
entially affected compared with cholesterol efflux.
For a balanced interpretation of our results the following points should be taken into account. (i) We 
demonstrate that ESRD-HDL is dysfunctional in mediating RCT in wild-type mice. RCT in mice largely 
depends on HDL and the HDL selective uptake receptor SR-BI. In contrast, in humans RCT is mainly based 
Figure 3. Oxidation of HDL in vitro results in impaired cholesterol uptake as well as delivery properties. 
(a) Cholesterol efflux from primary mouse peritoneal macrophages towards native, control HDL compared 
with control HDL following HOCl incubation (n = 10). (b) Cellular SR-BI mediated selective cholesterol uptake 
form control HDL or HOCl-modified HDL (n = 10) into ldla cells stably transfected with SR-BI. Data are 
presented as means ± SEM. **p < 0.01.
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on the LDL receptor mediating hepatic cholesterol uptake following transfer of cholesteryl esters out of HDL 
into apoB-containing lipoproteins by the cholesteryl ester transfer protein (CETP), which is not expressed in 
rodents36. Although ESRD-HDL apparently has a decreased interaction with several relevant components of the 
HDL metabolism system, it remains to be formally established that also in humans ESRD-HDL is defective in 
mediating in vivo RCT. (ii) In addition, we focussed in our in vitro studies on the classical RCT pathway, inves-
tigating macrophage efflux and hepatic uptake. We did not assess a contribution of transintestinal cholesterol 
excretion (TICE) to RCT, which might also have relevance here37. In previous work, we estimated the contribu-
tion of TICE to RCT to be around 30% under baseline conditions in wild-type mice4, while others found higher 
values38. However, results from lipoprotein kinetic studies indicate that HDL does not represent the lipoprotein 
subclass that donates cholesterol to the TICE pathway4,39, at least not directly. In a system expressing CETP such 
as humans, this contribution might be higher, but this questions remains to be experimentally answered. (iii) 
Furthermore, the patient and the control group differed in several aspects other than the presence/absence of 
ESRD such as diabetes, smoking or use of lipid lowering medication and we cannot formally exclude that these 
differences impact the results. However, there were no differences within the ESRD group between either smok-
ers/non-smokers, diabetic/non-diabetic patients and patients with or without lipid lowering medication (data not 
shown). Furthermore, also the results for cholesterol efflux as well as selective uptake were not different between 
ESRD patients displaying all additional risk factors combined (smoking, diabetes, lipid lowering medication) and 
those without, while each ESRD group differed significantly from controls (Supplemental Figure S1). These data 
indicate that the presence of ESRD might have a substantially stronger effect on the impairment of HDL function 
than any of these potential confounders. Also, none of the conclusions changed when the smokers were excluded 
from analysis (data not shown). (iv) The design of our study does not enable us to draw a firm conclusion, if the 
observed differences in HDL function are due to the hemodialysis treatment or the presence of ESRD. Future 
studies including patients with ESRD naïve to hemodialysis are warranted to address this issue.
In summary, our data demonstrate that HDL from ESRD patients is extensively oxidatively modified and dis-
plays reduced efficacy in key protective functions related to CVD, namely promoting (i) cellular cholesterol efflux, 
(ii) SR-BI-mediated cholesterol delivery and (iii) overall functional RCT in vivo. These results might have major 
implications to explain the excessive increase in CVD risk in uremic patients.
Materials and Methods
Patients and control subjects. EDTA plasma was collected under fasting conditions from patients with 
ESRD and age- and sex-matched controls (n = 15 each, see Supplemental Table S1 for clinical and biochemical 
characteristics). Blood samples were placed on ice immediately after collections and stored at − 80 °C until anal-
ysis. Patients and controls were in a stable clinical condition and free from infectious complications for at least 
3 months. None of the ERSD patients had residual renal function. Blood samples of the ESRD group were taken 
before regular hemodialysis sessions. Informed consent was obtained from all subjects. Blood collection was 
approved by the responsible medical ethics committee of the Charité Berlin and methods were carried out in 
accordance with the approved guidelines.
Cholesterol efflux experiments. Thioglycollate-elicited mouse peritoneal macrophages40 were loaded 
with 3H-cholesterol (1 μ Ci/ml, NEN Life Sciences Products), and 50 μ g acetylated LDL for 22 h as described14 
followed by equilibration in RPMI with 0.2% BSA for 18 h. Following another wash with PBS, acceptors were 
added (individual HDL samples isolated by ultracentrifugation as detailed below, 50 μ g of protein, experiments 
were performed in triplicates). After 5 h the supernatant was taken off and radioactivity within the medium was 
determined by liquid scintillation counting (Beckman LS6500, Beckman Instruments, Palo Alto, CA). Next, 0.1 M 
NaOH was added to cells, plates were incubated for 30 min at room temperature and the radioactivity remaining 
within the cells was then also assessed by liquid scintillation counting. Efflux is given as the percentage of counts 
recovered from the medium in relation to the total counts present on the plate (sum of medium and cells). Values 
Figure 4. HDL oxidized in vitro is defective in mediating in vivo RCT. Mice injected with macrophage foam 
cells loaded with 3H-cholesterol were infused with either control HDL or HOCl-modified HDL as detailed in 
methods. (a) HOCl-modified HDL had a significantly decreased capacity to mobilize macrophage-derived 
3H-cholesterol to the plasma compartment compared with native HDL at the 4 h time point (p < 0.05). (b) Fecal 
3H-cholesterol tracer recovery in the neutral sterol fraction, (c) Fecal 3H-cholesterol tracer recovery in the bile 
acid fraction. Data are presented as means ± SEM, n = 8 mice/group. *p < 0.05, **p < 0.01.
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for unspecific efflux determined as release of 3H-cholesterol from macrophages in the absence of HDL were sub-
tracted from the individual values.
HDL uptake experiments. LdlA cells lacking LDL receptor expression as well as ldlA cells stably trans-
fected with a murine SR-BI cDNA (ldlA[mSR-BI]) were kindly provided by Dr. Monty Krieger (MIT, Boston, 
USA) and cultured as described41. For HDL cholesterol uptake experiments, 5% lipoprotein-depleted serum was 
used. HDL was isolated from individual plasma samples as described below and labeled with cholesteryl hexade-
cyl ether (cholesteryl-1,2-3H, NEN Life Sciences Products), a non-hydrolyzable analogue of cholesteryl ester with 
identical selective uptake properties as 3H-cholesteryl ester, essentially as described42,43. Ten μ g/ml of 3H-CE HDL 
was added to the cells, experiments were performed in duplicates. After a 5-h incubation, the cells were washed 
three times with PBS (pH 7.4) and lysed with 0.5 ml of 0.1 M NaOH. Tracer uptake was calculated as counts recov-
ered from the cells as percentage of the total dose (counts from cells added to the counts from media).
HDL composition analysis. For the analysis of HDL composition, HDL was isolated from 200 μ l of plasma 
by tabletop sequential ultracentrifugation (1.063 < d < 1.21) as described44, and total and free cholesterol, phos-
pholipids and triglycerides were determined enzymatically using commercially available reagents (Wako Pure 
Chemical Industries, Neuss, Germany). Protein concentrations were measured with the BCA assay (Pierce, 
Rockford, IL, USA). Commercially available ELISA kits were used according to the manufacturer’s instructions 
to determine human SAA (Biosupply, Bradford, UK) and apoC-III (Abcam, Cambridge, UK) in HDL.
In vivo RCT. C57BL/6 J mice, 8 weeks of age, were purchased from Charles River (Sulzfeld, Germany). The 
animals were kept in animal rooms with alternating 12-hour periods of light (from 7:00 a.m. to 7:00 p.m.) and 
dark (from 7:00 p.m. to 7:00 a.m.), with ad libitum access to water and mouse chow diet (Arie Blok, Woerden, 
The Netherlands). Animal experiments were performed in accordance with the national laws. All protocols were 
approved by the responsible ethics committees of the Landesamt für Gesundheit, Ernährung und technische 
Sicherheit Berlin (LAGETSI) and the University of Groningen. Thioglycollate-elicited macrophages were isolated, 
cultured and loaded with AcLDL and 3H-cholesterol exactly as detailed above. At the end of the equilibration, 
macrophages were carefully harvested from the plate and injected intraperitoneally into mice (2 × 10E6 cells/
mouse). Directly following the i.p. injection of the macrophages, individually housed mice were administered 
i.v. either PBS (200 μ l) or pooled HDL (200 μ l) either from the ESRD patients group or from the group of control 
subjects at a dose of 2 mg HDL cholesterol/mouse. The choice to base injections on HDL cholesterol was made 
to be able to detect potential functional differences of HDL independent of the established clinical biomarker 
HDL cholesterol, whose validity has recently been called into question36. Injections were repeated at 24 h. Blood 
samples were drawn at time points 0 h, 4 h, 24 h and 48 h and tracer within plasma was determined by liquid scin-
tillation counting. After 48 h, mice were sacrificed, the liver was harvested and total feces produced over the 48 h 
period of the experiment were collected.
Radioactivity in plasma was counted directly, counts for 3H-cholesterol taken up by the liver were determined 
by incubating a piece of liver with Solvable (Packard, Meriden, CT, USA) according to the manufacturer’s instruc-
tions to dissolve the tissue as previously published45. Counts recovered from a respective piece of liver were back-
calculated to total liver mass and expressed as percent of injected dose per whole organ. Feces were thoroughly 
dried, ground and aliquots were separated into the bile acid and the neutral sterol fractions46. Counts recovered 
from the respective aliquots were related to the total amount of feces produced within 24 h and expressed as per-
centage of the injected radiotracer dose.
In vitro oxidative modification of HDL. Oxidized HDL was generated following a previously published 
procedure47. Briefly, 1 mg/ml of total HDL protein isolated from healthy controls (1.063 < d < 1.21) was incubated 
with NaOCl solution at a molar ratio of 200 for 60 min at 37 °C, adjusted to a final pH of 7.4. Preparations of mod-
ified HDL were dialyzed against PBS and used within 24 h. For uptake experiments, oxidized HDL were labeled 
with cholesteryl hexadecyl ether as described above.
Statistical analysis. Statistical analyses were performed using the statistical package for social sciences 
(SPSS; SPSS Inc., Chicago, IL). Data are presented as means ± SEM. Statistical differences between two groups 
were assessed using the Mann-Whitney U-test. To compare more than two groups ANOVA followed by a 
Bonferroni post-hoc test was used. Statistical significance for all comparisons was assigned at P < 0.05.
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